tiprankstipranks
Advertisement
Advertisement

IRD Stock Latest News

Oppenheimer bullish on Opus Genetics, initiates with an Outperform
The FlyOppenheimer bullish on Opus Genetics, initiates with an Outperform
11d ago
IRD
Opus Genetics initiated with an Outperform at Oppenheimer
PremiumThe Fly
Opus Genetics initiated with an Outperform at Oppenheimer
11d ago
IRD
Opus Genetics files to sell 7.37M shares of common stock for holders
PremiumThe Fly
Opus Genetics files to sell 7.37M shares of common stock for holders
13d ago
IRD
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
PremiumCompany Announcements
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
15d ago
IRD
VTRS
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch
PremiumCompany Announcements
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch
15d ago
IRD
Opus Genetics price target raised to $10 from $8 at Wedbush
PremiumThe FlyOpus Genetics price target raised to $10 from $8 at Wedbush
15d ago
IRD
Buy Rating on Opus Genetics Driven by Advancing Gene Therapy Pipeline, Near‑Term Clinical Catalysts, and Solid Cash Runway
Premium
Ratings
Buy Rating on Opus Genetics Driven by Advancing Gene Therapy Pipeline, Near‑Term Clinical Catalysts, and Solid Cash Runway
16d ago
IRD
Opus Genetics: Advancing Late-Stage Gene Therapy Pipeline and 2026 Data Catalysts Support Buy Rating and $10 Target
Premium
Ratings
Opus Genetics: Advancing Late-Stage Gene Therapy Pipeline and 2026 Data Catalysts Support Buy Rating and $10 Target
16d ago
IRD
Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year
PremiumThe Fly
Opus Genetics reports FY25 EPS (80c) vs ($2.15) last year
17d ago
IRD
Opus Genetics price target raised to $12 from $7 at BTIG
PremiumThe Fly
Opus Genetics price target raised to $12 from $7 at BTIG
25d ago
IRD
Opus Genetics announces initial data from Phase 1/2 study of OPGx-BEST1
PremiumThe Fly
Opus Genetics announces initial data from Phase 1/2 study of OPGx-BEST1
28d ago
IRD
Buy Rating on IRD Driven by Low-Risk Presbyopia Launch and High-Potential BEST1 Gene Therapy Pipeline
PremiumRatings
Buy Rating on IRD Driven by Low-Risk Presbyopia Launch and High-Potential BEST1 Gene Therapy Pipeline
30d ago
IRD
Opus Genetics says FDA accepts sNDA for phentolamine ophthalmic solution 0.75%
PremiumThe FlyOpus Genetics says FDA accepts sNDA for phentolamine ophthalmic solution 0.75%
30d ago
IRD
Opus Genetics Closes $25 Million Series B Financing
Premium
Company Announcements
Opus Genetics Closes $25 Million Series B Financing
1M ago
8K
IRD
Opus Genetics prices 7.37M Preferred Stock at $3.39 in private placement
Premium
The Fly
Opus Genetics prices 7.37M Preferred Stock at $3.39 in private placement
1M ago
IRD
Opus Genetics initiated with an Outperform at LifeSci Capital
PremiumThe Fly
Opus Genetics initiated with an Outperform at LifeSci Capital
1M ago
IRD
Opus Genetics: Favorable Risk‑Reward in OPGx-BEST1 Gene Therapy Underpins Buy Rating and $6 Price Target
PremiumRatings
Opus Genetics: Favorable Risk‑Reward in OPGx-BEST1 Gene Therapy Underpins Buy Rating and $6 Price Target
2M ago
IRD
Opus Genetics: Validated AAV Platform and High-Value IRD Pipeline Underpin Buy Rating and Attractive Risk‑Reward
PremiumRatings
Opus Genetics: Validated AAV Platform and High-Value IRD Pipeline Underpin Buy Rating and Attractive Risk‑Reward
2M ago
IRD
Opus Genetics launches gene therapy clinical trial for retinitis pigmentosa
PremiumThe Fly
Opus Genetics launches gene therapy clinical trial for retinitis pigmentosa
2M ago
IRD
Opus Genetics initiated with a Buy at BTIG
PremiumThe FlyOpus Genetics initiated with a Buy at BTIG
2M ago
IRD
Opus Genetics Highlights Gene Therapy Strategy at JPM Conference
Premium
Company Announcements
Opus Genetics Highlights Gene Therapy Strategy at JPM Conference
2M ago
8K
IRD
Opus Genetics Details 2025 Progress and 2026 Milestones
Premium
Company Announcements
Opus Genetics Details 2025 Progress and 2026 Milestones
3M ago
8K
IRD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >